Business
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and ...
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA.","length":420,"tagName":"p"},{"type":"text","content":"As part of the event, Sandra Silberman, MD, PhD, Chief Medical Officer of CNS will give an oral presentation titled, "The Use of Traditional Chemotherapy with Activity In the Treatment of Glioblastoma: Novel Formulations of an Anthracylcine & a Taxane That Appear to Cross the Blood-Brain Barrier," on Thursday, February 20, 2025 at 10:45 AM ET.","length":359,"tagName":"p"},{"type":"text","content":"As part of her presentation, Dr. Silberman will discuss how anthracyclines and taxanes have been indispensable in the treatment of cancer. Despite advancements, anthracyclines and taxanes have not been demonstrated to cross the Blood-Brain Barrier (BBB) in the absence of manipulation, however Dr. Silberman will provide an overview of the Company's reformulated anthracycline and a taxane currently in development, both of which appear to have significant penetration of the BBB and activity in GBM.","length":504,"tagName":"p"},{"type":"text","content":"The Company's lead program, Berubicin, is an anthracycline with demonstratable efficacy in Phase 1, and as previously announced in April 2024, completed enrollment with 252 patients in its potentially pivotal study of evaluating Berubicin vs. Lomustine for the treatment of GBM. CNS Pharmaceuticals expects to report primary analysis data from this study in the first half of 2025. For more information about this trial, visit clinicaltrials.gov and reference identifier NCT04762069.","length":487,"tagName":"p"},{"type":"text","content":"Additionally, the Company is advancing TPI 287, an abeotaxane that has shown significant activity in a Phase 1b study. CNS Pharmaceuticals plans to engage the FDA and obtain feedback on the design of a study focused on the registration of TPI 287 in GBM.","length":254,"tagName":"p"},{"type":"text","content":"The FDA has granted CNS Pharmaceuticals Fast Track Designation for...